Latest research on Betaseron

Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD

Betaseron interactions

Patients with a diagnosis of RRMS were eligible if they had been continuously treated with an approved DMT—interferon (IFN) (Avonex, Betaferon, Extavia, or Rebif) or GA (Copaxone)—for at least 30 days, and if informed consent was given prior to study inclusion. [source, 2016]
Of the thirty-three RR-MS patients, fourteen patients were on interferon-β1a (Avonex, Biogen Idec, Cambridge, MA USA), ten patients were on interferon-β1a (Rebif, Merck Serono, Rockland, MA, USA), seven patients were on interferon-β1a (Betaseron, Bayer HealthCare Pharmaceuticals, Montville, NJ, USA), ten patients were on glatiramer acetate (Copaxone, Teva pharmaceuticals, North Wales, PA, USA) and one patient was on natalizumab (Tysabri, Biogen Idec, Cambridge, MA USA). [source, 2015]
Of the twelve PP-MS patients, four were on interferon-β1a (Avonex, Biogen Idec, Cambridge, MA USA), two patients were on interferon-β1a (Rebif, Merck Serono, Rockland, MA, USA), four patients were on interferon-β1a (Betaseron, Bayer HealthCare Pharmaceuticals, Montville, NJ, USA) and two patients were on glatiramer acetate (Copaxone, Teva pharmaceuticals, North Wales, PA, USA). [source, 2015]
We found that levels of TROVE2, SSB, poly(A) + Y1 RNA and poly(A) + U1 snRNA were close to CTRL levels in RRMS subjects on Betaseron therapy compared to RRMS subjects on either Copaxone or no immunomodulatory therapy (Figure 6A, B). [source, 2015]
The interferons were injected second daily (Betaferon or Betaseron), thrice weekly (Rebif), or weekly (Avonex), whereas glatiramer acetate (Copaxone) was initially shown to be effective with daily administration. [source, 2015]
As well as the injectable therapies that have a long history of use as first-line treatments (Betaseron, Rebif, Avonex, Copaxone, Extavia––‘BRACE’), several intravenous or oral therapy options have become available in recent years: natalizumab (Tysabri®; Biogen Idec, initially 2004, then 2006 following temporary withdrawal for safety review); alemtuzumab [Lemtrada®; Sanofi, 2013––European Union (EU) only]; fingolimod (Gilenya®; Novartis, 2010––different indications in the USA and the EU); teriflunomide (Aubagio®; Sanofi, 2012), and dimethyl fumarate (DMF; Tecfidera®; Biogen Idec, 2013) [14]. [source, 2014]
Relatively few head-to-head studies have been conducted among the BRACE therapies and discussion here is confined to those involving IFN beta-1b: versus IFN beta-1a IM, the Independent Comparison of Interferons (INCOMIN) trial [40]; versus IFN beta-1a SC [41]; versus IFN beta-1a both IM and SC [42]; and versus GA, the Betaferon Efficacy Yielding Outcomes of a New Dose (BEYOND; ClinicalTrials.gov #NCT00099502) trial [43] and the Betaseron versus Copaxone in Multiple Sclerosis with Triple-Dose Gadolinium and 3-Tesla MRI Endpoints (BECOME; ClinicalTrials.gov #NCT00176592) trial [44]. [source, 2014]
There are two types of therapeutic rhIFN-β in clinical use: rhIFN-β 1a (Avonex and Rebif), which is produced in CHO cells and is singly glycosylated, and rhIFN-β 1b (Betaseron), which is produced in Escherichia coli and is not glycosylated [14]–[16]. [source, 2014]
Currently available DMTs include glatiramer acetate (GA; Copaxone, Teva Pharmaceuticals USA, Inc., North Wales, PA), intramuscular interferon beta-1a (IFNβ-1a IM; Avonex, Biogen Idec, Cambridge, MA), subcutaneous interferon beta-1a (IFNβ-1a SC; Rebif, EMD Serono Inc., Rockland, MA), interferon beta-1b (IFNβ-1b; Betaseron, Bayer Healthcare Pharmaceuticals, Inc., Montville, NJ; Extavia; Novartis Pharmaceutical Corporation, East Hanover, NJ), natalizumab (NZ; Tysabri, Biogen Idec, Cambridge, MA), fingolimod (FG; Gilenya, Novartis Pharmaceutical Corporation, East Hanover, NJ), teriflunomide (TF; Aubagio, Genzyme Corporation, Cambridge, MA) and dimethyl fumarate (DF; Tecfidera, Biogen Idec, Cambridge, MA). [source, 2014]
For the purpose of analysis, participants were categorised according to whether they currently took one of the interferons (one of the currently licensed interferon beta preparations: Avonex, Rebif, Betaferon or Betaseron), a disease modifying drug other than an interferon, or “other” (including those who took a non disease modifying drug or who took none). [source, 2014]